Good afternoon :)
Place Order
Add to Watchlist

Zydus Lifesciences Ltd

ZYDUSLIFE

Zydus Lifesciences Ltd

ZYDUSLIFE
Health CarePharmaceuticals
LargecapWith a market cap of ₹92,789 cr, stock is ranked 88
Moderate RiskStock is 2.37x as volatile as Nifty
922.151.58% (-14.85)
922.151.58% (-14.85)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Health CarePharmaceuticals
LargecapWith a market cap of ₹92,789 cr, stock is ranked 88
Moderate RiskStock is 2.37x as volatile as Nifty
Scorecard

Performance

Avg

Price return has been average, nothing exciting

Valuation

High

Seems to be overvalued vs the market average

Growth

Low

Lagging behind the market in financials growth

Profitability

High

Showing good signs of profitability & efficiency

Entry point

Avg

The stock is overpriced but is not in the overbought zone

Red flags

Low

No red flag found

How to use scorecard? Learn more

Health CarePharmaceuticals
LargecapWith a market cap of ₹92,789 cr, stock is ranked 88
Moderate RiskStock is 2.37x as volatile as Nifty

Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
31.204.710.65%
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
51.185.820.57%

Forecast & Ratings

Detailed Forecast 
48%
Analysts have suggested that investors can buy this stock

from 27 analysts

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Zydus Lifesciences Ltd is an India-based life sciences company. The Company has a pipeline for Biologics and Vaccines.

Investor Presentation

View older 

Sep 17, 2023

PDF
View Older Presentations

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

Forecasts

Price

Revenue

Earnings

Income

Balance Sheet

Cash Flow

Income Statement

Industry refers to the sub-sector this company belongs to.

Lower than Industry Revenue Growth

A higher-than-industry revenue growth represents increased potential for the company to increase their market share

Over the last 5 years, revenue has grown at a yearly rate of 7.71%, vs industry avg of 8.36%

Decreasing Market Share

Market share is the percentage of an industry's total sales going to a particular company. It gives a general idea of the size of a company v/s its competitors

Over the last 5 years, market share decreased from 5.92% to 5.34%

Lower than Industry Net Income

Net income is equal to net earnings (profit) less expenses. This number is an important measure of how profitable the company is

Over the last 5 years, net income has grown at a yearly rate of 2%, vs industry avg of 9.82%

Loading...

Financial YearFY 2015FY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023TTM
Total Revenue8,707.009,542.409,504.9012,018.1013,366.7014,367.0014,449.1017,693.0017,424.0019,211.50
Raw Materialssubtract3,293.703,107.003,557.704,437.404,826.105,013.804,958.305,907.506,072.0014,634.50
Power & Fuel Costsubtract159.20168.80174.50226.30247.20268.80246.90315.00361.60
Employee Costsubtract1,208.501,263.701,485.201,854.502,124.102,395.802,295.102,434.102,765.60
Selling & Administrative Expensessubtract1,523.401,824.101,648.601,944.701,970.302,384.802,237.402,210.602,697.90
Operating & Other expensessubtract721.50735.20609.10613.301,024.801,770.101,551.80902.002,089.20
Depreciation/Amortizationsubtract287.30292.10373.30538.80598.60696.50669.60713.00722.70737.40
Interest & Other Itemssubtract67.9052.8044.6091.10193.50341.80158.80127.00129.9074.30
Taxes & Other Itemssubtract294.90164.80124.20536.20533.30318.80197.60596.50624.80791.50
EPS11.2418.8914.5317.3518.0611.4920.8443.8319.2629.38
DPS2.403.203.203.503.503.503.502.506.006.00
Payout ratio0.210.170.220.200.190.300.170.060.310.20

Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2022

Annual report

PDF

Investor Presentation

May 20PDF
Feb 3PDF
Oct 29PDF
Aug 11PDF
FY 2023

Annual report

PDF

Investor Presentation

May 18PDF
Feb 3PDF
Nov 11PDF
Aug 10PDF
FY 2024

Annual Report Pending

Investor Presentation

Sep 17PDF
Aug 11PDF
 

Peers & Comparison

Comparing 3 stocks from 
Health CarePharmaceuticals

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Zydus Lifesciences Ltd47.334.710.65%
Sun Pharmaceutical Industries Ltd43.126.160.76%
Cipla Ltd38.784.580.63%
Dr Reddy's Laboratories Ltd21.964.250.67%

Price Comparison

Compare ZYDUSLIFE with any stock or ETF
Compare ZYDUSLIFE with any stock or ETF
ZYDUSLIFE
Loading...

Shareholdings

Promoter Holdings Trend

Total Promoter Holding

Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding

Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Institutional Holdings Trend

Total Retail Holding

Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Foreign Institutional Holding

Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding74.98%6.71%5.92%5.72%6.66%

Jun 2023

Sep 2023

Dec 2023

Mar 2024

Shareholding History

Dec '22MarJunSepDec '23Mar2.52%3.42%4.04%4.86%5.00%5.72%

Mutual Funds Holding Trend

Mutual Fund Holding

Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

Top 5 Mutual Funds holding Zydus Lifesciences Ltd




Funds (Top 5)Market-cap heldWeight3M holding changePortfolio rank
(3M change)
Kotak Flexicap Fund - Growth - Direct Plan

Growth
1.2105%2.45%0.61%15/64 (+2)
Parag Parikh Flexi Cap Fund - Growth - Direct Plan

Growth
0.8336%1.28%0.24%21/80 (+2)
KOTAK EMERGING EQUITY SCHEME - DIRECT PLAN - GROWTH

Growth
0.4618%1.08%0.28%26/90 (+5)

Compare 3-month MF holding change on Screener

Insider Trades & Bulk Deals

Loading...

smallcases

Looks like this stock is not in any smallcase yet.

Events

Dividend Trend

No Trend In Dividends

Dividends are the portion of earnings that a company distributes to all its shareholders every year

ZYDUSLIFE has shown inconsistent dividend trend over the last 5 years

Dividend Yield

Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation

Current dividend yield is 0.65%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹6.55 every year

Dividends

Corp. Actions

Announcements

Legal Orders

Upcoming Dividends

No upcoming dividends are available

Past Dividends

Cash Dividend

Ex DateEx DateJul 28, 2023

Final
Final | Div/Share: ₹6.00

Dividend/Share

6.00

Ex DateEx Date

Jul 28, 2023

Cash Dividend

Ex DateEx DateJul 28, 2022

Final
Final | Div/Share: ₹2.50

Dividend/Share

2.50

Ex DateEx Date

Jul 28, 2022

Cash Dividend

Ex DateEx DateJul 28, 2021

Final
Final | Div/Share: ₹3.50

Dividend/Share

3.50

Ex DateEx Date

Jul 28, 2021

Cash Dividend

Ex DateEx DateMar 23, 2020

Interim
Interim | Div/Share: ₹3.50

Dividend/Share

3.50

Ex DateEx Date

Mar 23, 2020

Cash Dividend

Ex DateEx DateJul 25, 2019

Final
Final | Div/Share: ₹3.50

Dividend/Share

3.50

Ex DateEx Date

Jul 25, 2019